Stock Analiz

Kazia Therapeutics Ltd. KZIA

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$6.62Market cap $103M
Open the interactive analysis →

Kazia Therapeutics Ltd. (KZIA) is a healthcare company listed in the US with a market value of about $103M. In fiscal year 2025 it had revenue of $27426 and net income of -$14M, a net margin of -49290.5%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).

A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Kazia Therapeutics

Kazia Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $301926 in 2016 to $27426 in 2025, a decline of about 23.4% a year. It was profitable in 0 of the last 10 years in our data.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3,753.0
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)-98.2%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-16835.4%
ROIC (5-yr avg.)—
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$27426$2M$0$0$11M——$87875$191347$301926
Net income-$14M-$18M-$14M-$17M-$6M-$9M-$7M-$4M-$8M-$9M
Free cash flow————————-$9M-$9M
EPS (diluted)$-0.87$-1.15$-0.87$-1.11$-0.41$-0.55$-0.46$-0.29$-0.53$-0.58
Net margin-49290.5%-1160.2%——-55.5%——-5074.8%-4285.1%-2971.2%
ROIC——————————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Kazia Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Kazia Therapeutics pay a dividend?

Not currently.

Is Kazia Therapeutics a good stock to buy?

We do not give buy or sell advice. Kazia Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.